Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

Susan O'Brien, Joseph O. Moore, Thomas E. Boyd, Loree M. Larratt, Aleksander Skotnicki, Benjamin Koziner, Asher A. Chanan-Khan, John F. Seymour, Robert G Bociek, Steve Pavletic, Kanti R. Rai

Research output: Contribution to journalArticle

247 Citations (Scopus)

Abstract

Purpose: Expression of Bcl-2 protein is associated with chemotherapy resistance and decreased survival in chronic lymphocytic leukemia (CLL). We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL. Patients and Methods: Patients had received at least one prior fludarabine-containing regimen and were stratified on the basis of prior fludarabine response, number of prior regimens, and duration of response to last prior therapy. Patients were randomly assigned to 28-day cycles of fludarabine 25 mg/m2/d plus cyclophosphamide 250 mg/m 2/d administered intravenously for 3 days with or without oblimersen 3 mg/kg/d as a 7-day continuous intravenous infusion (beginning 4 days before chemotherapy) for up to six cycles. The primary end point was the proportion of patients who achieved complete response (CR) or nodular partial response (nPR). Results: Of 241 patients randomly assigned, CR/nPR was achieved in 20 (17%) of 120 patients in the oblimersen group and eight (7%) of 121 patients in the chemotherapy-only group (P = .025). Achievement of CR/nPR was correlated with both an extended time to progression and survival (P < .0001). In patients who remained sensitive to fludarabine, oblimersen was associated with a four-fold increase in the CR/nPR rate and a significant survival benefit (P = .05). Oblimersen was frequently associated with thrombocytopenia and, rarely, tumor lysis syndrome and cytokine release reactions; the incidence of opportunistic infections and second malignancies was similar in both groups. Conclusion: The addition of oblimersen to fludarabine plus cyclophosphamide significantly increases the CR/nPR rate in patients with relapsed or refractory CLL (particularly fludarabine-sensitive patients), as well as response duration among patients who achieve CR/nPR.

Original languageEnglish (US)
Pages (from-to)1114-1120
Number of pages7
JournalJournal of Clinical Oncology
Volume25
Issue number9
DOIs
StatePublished - Mar 20 2007

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
Drug Therapy
Survival
fludarabine
oblimersen
Tumor Lysis Syndrome
Second Primary Neoplasms
Opportunistic Infections
Intravenous Infusions
Thrombocytopenia
Cytokines

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. / O'Brien, Susan; Moore, Joseph O.; Boyd, Thomas E.; Larratt, Loree M.; Skotnicki, Aleksander; Koziner, Benjamin; Chanan-Khan, Asher A.; Seymour, John F.; Bociek, Robert G; Pavletic, Steve; Rai, Kanti R.

In: Journal of Clinical Oncology, Vol. 25, No. 9, 20.03.2007, p. 1114-1120.

Research output: Contribution to journalArticle

O'Brien, Susan ; Moore, Joseph O. ; Boyd, Thomas E. ; Larratt, Loree M. ; Skotnicki, Aleksander ; Koziner, Benjamin ; Chanan-Khan, Asher A. ; Seymour, John F. ; Bociek, Robert G ; Pavletic, Steve ; Rai, Kanti R. / Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 9. pp. 1114-1120.
@article{a7c8df737f994ddfb88f4209db13a563,
title = "Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia",
abstract = "Purpose: Expression of Bcl-2 protein is associated with chemotherapy resistance and decreased survival in chronic lymphocytic leukemia (CLL). We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL. Patients and Methods: Patients had received at least one prior fludarabine-containing regimen and were stratified on the basis of prior fludarabine response, number of prior regimens, and duration of response to last prior therapy. Patients were randomly assigned to 28-day cycles of fludarabine 25 mg/m2/d plus cyclophosphamide 250 mg/m 2/d administered intravenously for 3 days with or without oblimersen 3 mg/kg/d as a 7-day continuous intravenous infusion (beginning 4 days before chemotherapy) for up to six cycles. The primary end point was the proportion of patients who achieved complete response (CR) or nodular partial response (nPR). Results: Of 241 patients randomly assigned, CR/nPR was achieved in 20 (17{\%}) of 120 patients in the oblimersen group and eight (7{\%}) of 121 patients in the chemotherapy-only group (P = .025). Achievement of CR/nPR was correlated with both an extended time to progression and survival (P < .0001). In patients who remained sensitive to fludarabine, oblimersen was associated with a four-fold increase in the CR/nPR rate and a significant survival benefit (P = .05). Oblimersen was frequently associated with thrombocytopenia and, rarely, tumor lysis syndrome and cytokine release reactions; the incidence of opportunistic infections and second malignancies was similar in both groups. Conclusion: The addition of oblimersen to fludarabine plus cyclophosphamide significantly increases the CR/nPR rate in patients with relapsed or refractory CLL (particularly fludarabine-sensitive patients), as well as response duration among patients who achieve CR/nPR.",
author = "Susan O'Brien and Moore, {Joseph O.} and Boyd, {Thomas E.} and Larratt, {Loree M.} and Aleksander Skotnicki and Benjamin Koziner and Chanan-Khan, {Asher A.} and Seymour, {John F.} and Bociek, {Robert G} and Steve Pavletic and Rai, {Kanti R.}",
year = "2007",
month = "3",
day = "20",
doi = "10.1200/JCO.2006.07.1191",
language = "English (US)",
volume = "25",
pages = "1114--1120",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

AU - O'Brien, Susan

AU - Moore, Joseph O.

AU - Boyd, Thomas E.

AU - Larratt, Loree M.

AU - Skotnicki, Aleksander

AU - Koziner, Benjamin

AU - Chanan-Khan, Asher A.

AU - Seymour, John F.

AU - Bociek, Robert G

AU - Pavletic, Steve

AU - Rai, Kanti R.

PY - 2007/3/20

Y1 - 2007/3/20

N2 - Purpose: Expression of Bcl-2 protein is associated with chemotherapy resistance and decreased survival in chronic lymphocytic leukemia (CLL). We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL. Patients and Methods: Patients had received at least one prior fludarabine-containing regimen and were stratified on the basis of prior fludarabine response, number of prior regimens, and duration of response to last prior therapy. Patients were randomly assigned to 28-day cycles of fludarabine 25 mg/m2/d plus cyclophosphamide 250 mg/m 2/d administered intravenously for 3 days with or without oblimersen 3 mg/kg/d as a 7-day continuous intravenous infusion (beginning 4 days before chemotherapy) for up to six cycles. The primary end point was the proportion of patients who achieved complete response (CR) or nodular partial response (nPR). Results: Of 241 patients randomly assigned, CR/nPR was achieved in 20 (17%) of 120 patients in the oblimersen group and eight (7%) of 121 patients in the chemotherapy-only group (P = .025). Achievement of CR/nPR was correlated with both an extended time to progression and survival (P < .0001). In patients who remained sensitive to fludarabine, oblimersen was associated with a four-fold increase in the CR/nPR rate and a significant survival benefit (P = .05). Oblimersen was frequently associated with thrombocytopenia and, rarely, tumor lysis syndrome and cytokine release reactions; the incidence of opportunistic infections and second malignancies was similar in both groups. Conclusion: The addition of oblimersen to fludarabine plus cyclophosphamide significantly increases the CR/nPR rate in patients with relapsed or refractory CLL (particularly fludarabine-sensitive patients), as well as response duration among patients who achieve CR/nPR.

AB - Purpose: Expression of Bcl-2 protein is associated with chemotherapy resistance and decreased survival in chronic lymphocytic leukemia (CLL). We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL. Patients and Methods: Patients had received at least one prior fludarabine-containing regimen and were stratified on the basis of prior fludarabine response, number of prior regimens, and duration of response to last prior therapy. Patients were randomly assigned to 28-day cycles of fludarabine 25 mg/m2/d plus cyclophosphamide 250 mg/m 2/d administered intravenously for 3 days with or without oblimersen 3 mg/kg/d as a 7-day continuous intravenous infusion (beginning 4 days before chemotherapy) for up to six cycles. The primary end point was the proportion of patients who achieved complete response (CR) or nodular partial response (nPR). Results: Of 241 patients randomly assigned, CR/nPR was achieved in 20 (17%) of 120 patients in the oblimersen group and eight (7%) of 121 patients in the chemotherapy-only group (P = .025). Achievement of CR/nPR was correlated with both an extended time to progression and survival (P < .0001). In patients who remained sensitive to fludarabine, oblimersen was associated with a four-fold increase in the CR/nPR rate and a significant survival benefit (P = .05). Oblimersen was frequently associated with thrombocytopenia and, rarely, tumor lysis syndrome and cytokine release reactions; the incidence of opportunistic infections and second malignancies was similar in both groups. Conclusion: The addition of oblimersen to fludarabine plus cyclophosphamide significantly increases the CR/nPR rate in patients with relapsed or refractory CLL (particularly fludarabine-sensitive patients), as well as response duration among patients who achieve CR/nPR.

UR - http://www.scopus.com/inward/record.url?scp=34047217206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047217206&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.07.1191

DO - 10.1200/JCO.2006.07.1191

M3 - Article

C2 - 17296974

AN - SCOPUS:34047217206

VL - 25

SP - 1114

EP - 1120

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -